The Clinical and Cost-Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia: an Evidence Review Group Evaluation of a NICE Single Technology Appraisal : Inotuzumab for the treatment of adult R/R B-cell ALL: an ERG perspective

Cox, Edward Miles, Wade, Rosalind Fay orcid.org/0000-0002-8666-8110, Peron, Mathilde Michelle Germaine et al. (4 more authors) (2019) The Clinical and Cost-Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia: an Evidence Review Group Evaluation of a NICE Single Technology Appraisal : Inotuzumab for the treatment of adult R/R B-cell ALL: an ERG perspective. PharmacoEconomics. ISSN 1179-2027

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © Springer Nature Switzerland AG 2019. This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details.
Keywords: Pharmacology,Health Policy,Public Health, Environmental and Occupational Health
Dates:
  • Published (online): 19 March 2019
Institution: The University of York
Academic Units: The University of York > Faculty of Social Sciences (York) > Centre for Health Economics (York)
The University of York > Faculty of Social Sciences (York) > Centre for Reviews and Dissemination (York)
Depositing User: Pure (York)
Date Deposited: 05 Jun 2019 16:00
Last Modified: 18 Aug 2019 23:53
Published Version: https://doi.org/10.1007/s40273-019-00779-4
Status: Published online
Refereed: Yes
Identification Number: https://doi.org/10.1007/s40273-019-00779-4
Related URLs:

Download

Accepted Version


Embargoed until: 19 March 2020

Filename: Revised_Inotuzumab_Review_01.02.2019.docx

Description: Revised Inotuzumab Review

Request a copy

Share / Export

Statistics